Bicara Therapeutics Inc (BCAX)

Nov 19, 2024

First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownWhat's Next? - MarketBeat

Nov 18, 2024

Nov 18, 2024

FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World

Nov 18, 2024

Nov 18, 2024

FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat

Nov 18, 2024

Nov 15, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat

Nov 15, 2024

Nov 13, 2024

Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks

Nov 13, 2024

Nov 12, 2024

Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Nov 12, 2024

Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha

Nov 12, 2024

Nov 12, 2024

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024

Nov 12, 2024

Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan

Nov 12, 2024

Nov 11, 2024

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times

Nov 11, 2024

Nov 09, 2024

Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World

Nov 09, 2024

Nov 06, 2024

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat

Nov 06, 2024

Nov 06, 2024

Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat

Nov 06, 2024

Nov 05, 2024

Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com

Nov 05, 2024

Nov 05, 2024

Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat

Nov 05, 2024

Oct 23, 2024

Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law

Oct 23, 2024

Oct 21, 2024

Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media

Oct 21, 2024

Oct 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat

Oct 18, 2024

Oct 16, 2024

Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 16, 2024

Oct 11, 2024

In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex

Oct 11, 2024

Oct 10, 2024

Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat

Oct 10, 2024

Oct 10, 2024

Down rounds don’t aid post-IPO performance - BioCentury

Oct 10, 2024

Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 08, 2024

Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com

Oct 08, 2024

Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com

Oct 08, 2024

Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential - Investing.com India

Oct 08, 2024

Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com

Oct 08, 2024

Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa

Oct 08, 2024

Oct 07, 2024

Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters

Oct 07, 2024

Oct 04, 2024

Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN

Oct 04, 2024

Oct 02, 2024

Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex

Oct 02, 2024

Sep 27, 2024

Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN

Sep 27, 2024

Sep 27, 2024

Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express

Sep 27, 2024

Sep 26, 2024

With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times

Sep 26, 2024

Sep 25, 2024

Bicara Therapeutics Rings the Opening Bell - Nasdaq

Sep 25, 2024

Sep 25, 2024

Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Sep 25, 2024

Sep 21, 2024

Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN

Sep 21, 2024

Sep 21, 2024

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com

Sep 21, 2024

Sep 19, 2024

James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 19, 2024

Sep 19, 2024

Upstream Bio goes public amid spate of IPOs - The Pharma Letter

Sep 19, 2024

Sep 18, 2024

Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 18, 2024

Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024

Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India

Sep 18, 2024

Sep 18, 2024

FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance

Sep 18, 2024

Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia

Sep 17, 2024

Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com

Sep 17, 2024

Sep 17, 2024

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance

Sep 17, 2024